Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Finished Goods came in at $15.3 million in Q1 2026, up 88.21% YoY from $8.1 million in Q1 2025, and down 5.43% on a QoQ basis from $16.2 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 4 years of Finished Goods data on file, last reported at $15.3 million in Q1 2026.
- Quarterly Finished Goods rose 88.21% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 88.21% YoY) and the FY2025 annual result came in at $16.2 million, up 68.7% from the prior year.
- Finished Goods retreated to $15.3 million in Q1 2026, from $16.2 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $16.2 million in Q4 2025 to a low of $8.1 million in Q1 2025.
- A 4-year average of $10.6 million and a median of $9.2 million in 2024 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2025 — Finished Goods fell 3.29% — and 2026, when it jumped 88.21%.
- Tracing CPRX's Finished Goods over 4 years: stood at $9.2 million in 2023, then grew by 4.55% to $9.6 million in 2024, then soared by 68.7% to $16.2 million in 2025, then slipped by 5.43% to $15.3 million in 2026.
- The last three Finished Goods figures came in at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.28 Mn |
| Dec 31, 2025 | 16.16 Mn |
| Sep 30, 2025 | 11.29 Mn |
| Jun 30, 2025 | 8.12 Mn |
| Mar 31, 2025 | 8.12 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 9.24 Mn |
| Jun 30, 2024 | 8.40 Mn |
| Dec 31, 2023 | 9.16 Mn |